[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
July 27, 2005

Vitamin E Supplementation, Cardiovascular Events, and Cancer

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;294(4):425-426. doi:10.1001/jama.294.4.425-a

To the Editor: I am concerned about a potential confounder in the randomized controlled trial by the initial Heart Outcomes Prevention Evaluation (HOPE) and HOPE−The Ongoing Outcomes (HOPE-TOO) trial investigators1 on long-term vitamin E supplementation and cardiovascular events and cancer. There was no presentation of the prevalence of glitazone use in both treatment groups, whether this variable was controlled for in the data analysis, or whether the patients who developed new-onset heart failure had been taking glitazone drugs. Similarly, a breakdown of the percentage of patients from the United States, Canada, and Brazil, in which these drugs were marketed differently, would have been helpful.

First Page Preview View Large
First page PDF preview
First page PDF preview
×